# Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis

> **NCT03156023** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 34 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Rozibafusp Alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03156023
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-14
- **Primary completion:** 2019-10-17
- **Final completion:** 2020-06-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03156023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03156023, "Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03156023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*